Our innovative, patented antibody allows us to personalize the blood serum marker levels and build an early detection strategy for women with dense breast tissue.
San Francisco, Calif. (PRWEB) January 12, 2016
OncoTAb, Inc., a University of North Carolina at Charlotte (UNCC) spin-out company, announced that CEO Rahul Puri will present the study findings of a non-invasive blood test to aid in the early detection of breast cancer in women with dense breast tissue at the 9th Annual OneMedForum in San Francisco. The presentation will take place today, January 12 at 2:45 p.m. and again on January 13 at 11:00 a.m. at the San Francisco Marriot Marquis.
Using a patented monoclonal antibody, known as TAB-004, the technology recognizes a tumor-specific biomarker found in all major breast cancer subtypes, including triple negative breast cancer (TNBC). Puri will present data highlighting TAB-004’s success in identifying breast cancer and discuss its future applications for targeted in-vivo imaging and tumor treatment. The Agkura™ Personalized Score will be available in Q1, 2016 as a supplement to mammography.
“According to The New England Journal of Medicine, mammograms of dense breast tissue miss 50 percent of all cancers detected less than a year after a negative test. Our innovative, patented antibody allows us to personalize the blood serum marker levels and build an early detection strategy for women with dense breast tissue,” said Puri. “The Agkura™ Personalized Score has received extensive support from clinicians, breast-density advocates and women concerned about their high tissue density and low mammography sensitivity.”
Investors interested in speaking with Rahul Puri may register online and set up a meeting with the following link: http://tinyurl.com/qzul24w.
This press release is neither an offer to sell nor the solicitation of an offer to buy shares or any other security in any jurisdiction.
About OncoTAb, Inc.
OncoTAb (http://www.oncotab.com) is a University of North Carolina at Charlotte (UNCC) spin-out company that has a patent-protected technology. Its applications span the life cycle of cancer patients, from detecting and locating cancer to treatment and monitoring for recurrence. The company is gearing up to launch its blood test to aid in the early detection of breast cancer in women with dense breast tissue. OncoTAb is in early stages of developing therapeutic applications, including development of Chimeric Antigen Receptor (CAR) engineered T-cells for Triple Negative Breast Cancer. The company is seeking to partner/license its technology for the development of an imaging application to detect cancer in women with dense breast tissue.